 |
|
Sumatriptan Injection Reduces Productivity Loss During a Migraine Attack
Results of a Double-blind, Placebo-Controlled Trial
Roger C. Cady, MD;
Robert Ryan, MD;
Priti Jhingran, PhD;
Stephen O'Quinn, PharmD;
D. Gayla Pait, MS
Arch Intern Med. 1998;158:1013-1018.
Objective To evaluate the impact of sumatriptan succinate injection compared with placebo on productivity loss during a migraine attack in the workplace.
Design Randomized, double-blind, placebo-controlled, parallel-group clinical trial.
Setting Fifteen clinical centers in the United States.
Patients One hundred thirty-five patients 18 years and older diagnosed as having migraine according to International Headache Society criteria.
Interventions Patients self-administered sumatriptan injection (6 mg) or matching placebo to treat a moderate or severe migraine occurring within the first 4 hours of a minimum 8-hour work shift.
Main Outcome Measures Mean productivity loss 2 hours after dosing and across the work shift; percentages of patients returning to normal work performance within 2 hours after dosing and across the work shift; percentages of patients experiencing headache relief (reduction of moderate or severe predose pain to mild or no pain) 1 and 2 hours after dosing.
Results Mean productivity loss was significantly (P .002) lower in the sumatriptan group compared with the placebo group both during the 2-hour postdose period (sumatriptan, 39 minutes; placebo, 54 minutes) and across the work shift (sumatriptan, 86 minutes; placebo, 168 minutes). Significantly (P<.001) greater percentages of patients in the sumatriptan group compared with the placebo group returned to normal work performance by 2 hours after dosing (sumatriptan, 52%; placebo, 9%) and across the work shift (sumatriptan, 66%; placebo, 18%). Significantly (P.001) greater percentages of patients in the sumatriptan group compared with the placebo group experienced headache relief 1 hour after dosing (sumatriptan, 69%; placebo, 18%) and 2 hours after dosing (sumatriptan, 79%; placebo, 32%).
Conclusion Sumatriptan reduced migraine-associated productivity loss during a minimum 8-hour work shift by approximately 50% compared with placebo and alleviated headache in more than three fourths of patients.
From the Headache Care Center, Springfield, Mo (Dr Cady), and Glaxo Wellcome Research Institute, Research Triangle Park, NC (Drs Jhingran and O'Quinn and Ms Pait). Dr Ryan is in private practice in St Louis, Mo.
RELATED LETTER
Reduction of Labor Costs Associated With Treating Migraine in the Workplace
Roger C. Cady
Arch Intern Med. 1999;159(2):197.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life
Lipton et al.
Neurology 2005;65:S50-S58.
ABSTRACT
| FULL TEXT
Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce
Stewart et al.
JAMA 2003;290:2443-2454.
ABSTRACT
| FULL TEXT
Evaluation of Migraineurs' Preferences for Naratriptan Over Conventional First-Line Agents
Powers et al.
Arch Fam Med 2000;9:753-757.
ABSTRACT
| FULL TEXT
Changes in Resource Use and Outcomes for Patients With Migraine Treated With Sumatriptan: A Managed Care Perspective
Lofland et al.
Arch Intern Med 1999;159:857-863.
ABSTRACT
| FULL TEXT
Reduction of Labor Costs Associated With Treating Migraine in the Workplace
Cady
Arch Intern Med 1999;159:197-197.
FULL TEXT
Headache in Women
JWatch Women's Health 1998;1998:20-20.
FULL TEXT
Sumatriptan Reduces Productivity Loss Due to Migraines
JWatch Women's Health 1998;1998:1-1.
FULL TEXT
Sumatriptan Improves Work Productivity In Migraine Patients
JWatch General 1998;1998:3-3.
FULL TEXT
|
